UNSPSC 51162637: Morclofone

This classification denotes an antitussive agent with the molecular formula C21H24ClNO5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) VY62TIB872, chemically known as 4-chloro-3,5-dimethoxy-4-(2-morpholinoethoxy)benzophenone but more generally known as morclofone, which bears US NIH Compound Identifier 35949. European Medicines Agency schedules Morclofone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09065MIG.

UNSPSC 51162637 Morclofone is a Commodity code that encompasses naloxone products and related pharmaceutical supplies procured by state and local health agencies to support overdose-response and community health initiatives. State and local governments buy naloxone in bulk quantities through competitive bidding processes, typically for distribution through public health departments, county community health facilities, and multistate cooperative purchasing vehicles. Issuing bodies include county health departments and state-administered cooperative purchasing alliances that coordinate pharmaceutical procurement across multiple jurisdictions. The work involves supplying finished pharmaceutical products with specified National Drug Codes (NDCs), managing compliance with Drug Supply Chain Security Act (DSCSA) requirements and current Good Manufacturing Practices (cGMP), and fulfilling quarterly or ongoing delivery schedules to designated health facilities.

Recent activity spans Florida and Minnesota. Seminole County, Florida posted IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to its Community Health Building in Sanford, Florida, with responses due July 26, 2023. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products across participating state and local government facilities including Oregon, with proposals due March 26, 2026. MMCAP requires vendors to maintain relationships with three authorized wholesalers (AmerisourceBergen Drug Corporation/Cencora, Cardinal Health 110 and 112, and Morris & Dickson Co., LLC) and evaluated proposals on price competitiveness (75 percent weight) and compliance with administrative, EDI, and pricing-format requirements. Both procurements required E-Verify certification, drug-free workplace compliance, and comprehensive liability insurance.